NRX Pharmaceuticals, Inc. NRXP 深 滬
等待開盤 02-10 09:30:00 美东时间
1.99
+0.080
+4.19%
華盛通- 最 高1.995
- 今 開1.94
- 成交量 46.56万股
- 最 低 1.82
- 昨 收 1.91
- 總市值 5891.42万
- 52周最高 3.84
- 市盈率 靜 --
- 換手率 1.57%
- 52周最低 1.58
- 委 比 -91.06%
- 總股本 2960.52万
- 歷史最高 769.90
- 量 比 0.70
- 振 幅 9.16%
- 歷史最低 1.58
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
01-15 17:47
NRx Uses Real-World Ketamine Data to Seek Faster FDA Approval for Suicide Treatment
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has licensed Real World Evidence (RWE) drawn from over 70,000 patients in the United States who were treated
01-14 20:04
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
美股大行评级 | 杰富瑞上调百度目标价从159美元升至181美元；花旗下调京东目标价从44美元下调至37美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从47美元升至48美元；BTIG：维持Hudson Pacific Properties"买入"评级，目标价从4.75美元升至26美元
01-05 13:52
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-02 21:26
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $48
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $47 to $48.
01-02 17:50
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $40 price target.
2025-12-16 20:09
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
